At RSNA, Bayer to Demonstrate Product Offerings and Announces Expanded AI Offering in Radiology

At RSNA, Bayer to Demonstrate Product Offerings and Announces Expanded AI Offering in Radiology

November 26, 2022 — As international imaging leaders gather for the 2022 Radiological Society of North America (RSNA) Annual Meeting, Bayer Radiology, a leader in diagnostic imaging, will present its portfolio of products and solutions designed to meet the most pressing needs facing the field of radiology. In addition, Bayer will present new scientific data on an investigational contrast agent. RSNA 2022 will take place from November 27 to December 1 in Chicago.

Bayer’s focus areas at RSNA represent the company’s commitment to help address staffing shortages with solutions focused on patient throughput and workflow efficiency to drive automation and standardization , investing in science for the benefit of patients and their doctors, and harnessing the vast potential of data and AI.

Next-generation CT technology and workflow solutions highlight integrated offerings that manage complexity and deliver accurate diagnostic information more efficiently.

Bayer’s introduction of Injector Management* software enables consistency and standardization by providing the ability to share common protocols across connected injectors. *not yet commercially available.

Bayer will showcase its next-generation CT technology, MEDRAD Centargo CT Injection System (Centargo) at RSNA (Centargo is 510(k) pending and not available for sale in the U.S. The latest addition to Bayer’s CT portfolio is designed to improve workflow efficiency with design features that work in conjunction with Bayer’s product portfolio to bring innovative technology to the imaging suite and introduce new technologies to the areas of patient setup .

EExpanding AI offerings on Calantic Digital Solutions

Bayer is also announcing collaboration agreements with application developers Quantib, ClariPi and EXINI Diagnostics to strategically expand the offering on its Calantic Digital Solutions medical imaging platform. The platform, which was launched recently, provides access to applications, including those enabled by AI, for medical imaging. With these new collaboration agreements, Bayer expands the options already available for chest and neurological diseases on the platform by including tools that aim to facilitate breast and prostate imaging.

Introducing the Calantic SPARK Application Accelerator Program

Additionally, Bayer recently launched Calantic SPARK, a new accelerator program for medical imaging application developers to further drive innovation in AI in radiology. The program will initially focus on North America and Europe and is expected to expand to other regions, including Asia-Pacific. Bayer offers a targeted program to accelerate market readiness for early-stage projects and deals, providing advice spanning medical, regulatory, reimbursement expertise and market access. Leveraging the thriving start-up ecosystem of AI in medical imaging, Calantic SPARK offers program participants a potential route to commercialization and distribution through Calantic Digital Solutions. Details of Calantic SPARK will be on display at Bayer’s booth as well as the AI ​​Showcase Theater at RSNA.

Corporate seminars

The role of a high relaxivity contrast agent in CNS and MRA imaging
Monday, November 28, 9:30 a.m. (CT)
Room: S102AB

From AI design to validation; The role of AI orchestration platforms
Presentation of the Al Showcase Theater
Monday, November 28, 1:00 p.m. (CT)
Room: S102AB

Sparks of collaboration, How Bayer engages with the startup ecosystem.
Monday, November 28, 11:00 a.m. (CT)
Venue: AI Theater

Liver Imaging Techniques and Considerations.
Tuesday, November 29, 10:30 a.m. (CT)
Virtual Product Theater

Drive AI innovation to assess reimbursable applications
Wednesday, November 30, 3:00 p.m. (CT)
Innovation Theater

Scientific presentation on a new experimental molecular entity

Bayer will present the results of the first clinical trial data on an investigational contrast agent. Gadoquatrane is a gadolinium-based contrast agent in Phase II development. The study examined the pharmacokinetics, including excretion routes, safety, and tolerability of gadoquatrane in healthy volunteers.

  • Session number: R5A-SPNR; 1st December ; 12:15 p.m. – 12:45 p.m., (CT)

For more information:

Find more RSNA22 coverage here

#RSNA #Bayer #Demonstrate #Product #Offerings #Announces #Expanded #Offering #Radiology

Leave a Comment

Your email address will not be published. Required fields are marked *